Ubix Therapeutics
PrivateLast Round
Growth Equity
Dec 23, 2024
Total Funding Raised
$46.3M
Company Overview
Ubix Therapeutics operates in Healthcare & Life Sciences and is based in Seoul. Its latest recorded funding round was a Growth Equity round in December 2024.
Ubix Therapeutics is a biotechnology company that develops novel anti-cancer therapies using its proprietary targeted protein degradation platform, Degraducer®.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ubix Therapeutics Comparables
Compare Ubix Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Prazer Therapeutics | 89% | |
| Cyrus Therapeutics | 88% | |
| Pin Therapeutics | 88% |
For institutional investors. Book with your work email.
Ubix Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Growth Equity | Dec 23, 2024 | ||||
| Series C | Jul 1, 2023 | ||||
| Series B | May 6, 2020 | ||||
| Series A | Feb 1, 2019 |
For institutional investors. Book with your work email.
Ubix Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KOTEC | Growth Equity |
| BNH INVESTMENT | Series C |
| UTC Investment | Series B, Series C |
| Premier Partners | Series B, Series A |
| QUAD Investment Management | Growth Equity |
| GeneN Investment Partners | Series C |
| Medytox Venture Investment | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 21, 2026
Monthly visitors increased 42% MoM to 4.8K.
- Jun 1, 2025
Monthly visitors increased 88% MoM, reaching 3K.
For institutional investors. Book with your work email.
Ubix Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ubix Therapeutics's valuation, stock price, and market status.
Is Ubix Therapeutics a public or private company?
Ubix Therapeutics is a private company.
What is the current stock price of Ubix Therapeutics?
Ubix Therapeutics is a private company, so its shares have no public market price. Caplight tracks Ubix Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ubix Therapeutics worth (valuation)?
Valuation information for Ubix Therapeutics is not publicly available.
Can I buy Ubix Therapeutics stock?
Ubix Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ubix Therapeutics's last funding round?
Ubix Therapeutics's most recent funding round was Growth Equity on December 23, 2024.
Who are the main investors in Ubix Therapeutics?
Key investors in Ubix Therapeutics include KOTEC, BNH INVESTMENT, UTC Investment, Premier Partners, QUAD Investment Management.
Will Ubix Therapeutics IPO soon?
No public IPO plans have been announced for Ubix Therapeutics.
How can I track Ubix Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Ubix Therapeutics's shares on secondary markets.